Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.
ACRS has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Canaccord Genuity Group started coverage on shares of Aclaris Therapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $10.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aclaris Therapeutics has a consensus rating of “Buy” and a consensus target price of $11.33.
Get Our Latest Research Report on ACRS
Aclaris Therapeutics Price Performance
Shares of Aclaris Therapeutics stock opened at $3.75 on Friday. The stock’s 50 day simple moving average is $5.11 and its 200-day simple moving average is $4.97. The stock has a market cap of $524.33 million, a P/E ratio of -6.47 and a beta of 0.87. Aclaris Therapeutics has a 1-year low of $2.10 and a 1-year high of $6.60.
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%. The firm had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $1.38 million. As a group, research analysts expect that Aclaris Therapeutics will post -0.62 EPS for the current fiscal year.
Institutional Investors Weigh In On Aclaris Therapeutics
Several large investors have recently added to or reduced their stakes in the business. Braidwell LP increased its holdings in Aclaris Therapeutics by 26.1% during the 2nd quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock worth $11,333,000 after purchasing an additional 443,232 shares during the period. Wellington Management Group LLP raised its position in Aclaris Therapeutics by 4.0% in the 2nd quarter. Wellington Management Group LLP now owns 267,498 shares of the biotechnology company’s stock valued at $1,415,000 after purchasing an additional 10,342 shares in the last quarter. Palo Alto Investors LP purchased a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at about $8,535,045. Jefferies Financial Group Inc. purchased a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at about $58,000. Finally, Bank of America Corp DE purchased a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at about $584,000. 98.34% of the stock is owned by hedge funds and other institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.
Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.
See Also
- Five stocks we like better than Aclaris Therapeutics
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
